GenapSys Announces Key Hire to Senior Management Team
Addition of Vice President Strengthens Application and Product Development of the GENIUS(tm) 110 DNA Sequencing system.
Redwood City, CA, September 25, 2014 --(PR.com)-- GenapSys Inc., the developer of the GENIUS DNA Sequencing System, today announced the appointment of Mark Pratt, Ph.D. as Vice President of Product Development.
In his new role, Dr. Pratt will be a member of the GenapSys leadership team reporting to Hesaam Esfandyarpour, PhD, Founder & CEO. Most recently, Dr. Pratt was Senior Director of Accuracy R&D at Personalis, where he led platform and assay R&D. Prior to Personalis, Dr. Pratt served in a leadership role at both Solexa, Inc. and Illumina, Inc. where he was responsible for Engineering Research. In his role at Illumina, Dr. Pratt was instrumental and held leadership positions in developing a series of Next Generation DNA Sequencing systems (NGS), including the HiSeq™ and MiSeq™ systems. Dr. Pratt earned a Ph.D. in Physics from UC Santa Barbara and later held a postdoctoral position at MIT.
With a footprint no bigger than an iPad, the portable GENIUS system will for the first time make DNA sequencing widely available to individual researchers, assay developers, and diagnostic laboratories. Building on over a decade of research, innovation, and development at Stanford University and GenapSys, the GENIUS system generates DNA Sequencing results faster and at a fraction of the cost of existing products on the market.
“Following our strong progress in the development of the GENIUS system, Mark’s addition to our team comes at a key point in time for GenapSys,” said Dr. Esfandyarpour. “As GenapSys plans the commercial launch of our GENIUS 110 DNA Sequencing System in 2015, Mark’s depth and breadth of experience in instrumentation, assays, and bioinformatics will enable us to offer a fuller set of NGS based solutions and help to accelerate the wide deployment of the GENIUS system.”
About GenapSys Inc.
GenapSys, headquartered in Redwood City, CA, is a venture backed privately-held company that is producing a market disrupting Genetic Testing system. The company’s first product, the GENIUS system, will enable Next Generation Sequencing users to replace today’s workflows that are tedious, expensive and time-consuming with a simple, cost-effective and fast process. Its patented GENIUS technology integrates advanced electronics, novel sensors, fluidics and analytics to dramatically reduce capital outlays and operating expenses for DNA and RNA sequencing. The GENIUS technology is protected by more than 40 patents and patent applications. GenapSys’s advisory board includes among others, Ron Davis, Director of Stanford Genome Technology Center, George Church, Professor of Genetics at Harvard Medical School, Eric Topol, Director of the Scripps Translational Science Institute, and Michael Snyder, Director of Stanford Center for Genomics and Personalized Medicine. For more information, visit our website at www.GenapSys.com.
In his new role, Dr. Pratt will be a member of the GenapSys leadership team reporting to Hesaam Esfandyarpour, PhD, Founder & CEO. Most recently, Dr. Pratt was Senior Director of Accuracy R&D at Personalis, where he led platform and assay R&D. Prior to Personalis, Dr. Pratt served in a leadership role at both Solexa, Inc. and Illumina, Inc. where he was responsible for Engineering Research. In his role at Illumina, Dr. Pratt was instrumental and held leadership positions in developing a series of Next Generation DNA Sequencing systems (NGS), including the HiSeq™ and MiSeq™ systems. Dr. Pratt earned a Ph.D. in Physics from UC Santa Barbara and later held a postdoctoral position at MIT.
With a footprint no bigger than an iPad, the portable GENIUS system will for the first time make DNA sequencing widely available to individual researchers, assay developers, and diagnostic laboratories. Building on over a decade of research, innovation, and development at Stanford University and GenapSys, the GENIUS system generates DNA Sequencing results faster and at a fraction of the cost of existing products on the market.
“Following our strong progress in the development of the GENIUS system, Mark’s addition to our team comes at a key point in time for GenapSys,” said Dr. Esfandyarpour. “As GenapSys plans the commercial launch of our GENIUS 110 DNA Sequencing System in 2015, Mark’s depth and breadth of experience in instrumentation, assays, and bioinformatics will enable us to offer a fuller set of NGS based solutions and help to accelerate the wide deployment of the GENIUS system.”
About GenapSys Inc.
GenapSys, headquartered in Redwood City, CA, is a venture backed privately-held company that is producing a market disrupting Genetic Testing system. The company’s first product, the GENIUS system, will enable Next Generation Sequencing users to replace today’s workflows that are tedious, expensive and time-consuming with a simple, cost-effective and fast process. Its patented GENIUS technology integrates advanced electronics, novel sensors, fluidics and analytics to dramatically reduce capital outlays and operating expenses for DNA and RNA sequencing. The GENIUS technology is protected by more than 40 patents and patent applications. GenapSys’s advisory board includes among others, Ron Davis, Director of Stanford Genome Technology Center, George Church, Professor of Genetics at Harvard Medical School, Eric Topol, Director of the Scripps Translational Science Institute, and Michael Snyder, Director of Stanford Center for Genomics and Personalized Medicine. For more information, visit our website at www.GenapSys.com.
Contact
Genapsys Inc.
Derek Kan
650-330-1096 x121
www.genapsys.com
Derek Kan
650-330-1096 x121
www.genapsys.com
Contact
Categories